185 related articles for article (PubMed ID: 33656535)
1. Comorbidities and malignancies negatively affect survival in myelodysplastic syndromes: a population-based study.
Rozema J; Hoogendoorn M; Kibbelaar R; van den Berg E; Veeger N; van Roon E
Blood Adv; 2021 Mar; 5(5):1344-1351. PubMed ID: 33656535
[TBL] [Abstract][Full Text] [Related]
2. A review of therapy-related myelodysplastic syndromes and acute myeloid leukaemia (t-MDS/AML) in Irish patients: a single centre experience.
Maung SW; Burke C; Hayde J; Walshe J; McDermott R; Desmond R; McHugh J; Enright H
Hematology; 2017 Jul; 22(6):341-346. PubMed ID: 28196450
[TBL] [Abstract][Full Text] [Related]
3. Comorbidities and survival in a large cohort of patients with newly diagnosed myelodysplastic syndromes.
Wang R; Gross CP; Halene S; Ma X
Leuk Res; 2009 Dec; 33(12):1594-8. PubMed ID: 19324411
[TBL] [Abstract][Full Text] [Related]
4. Combination of Frailty Status and Comorbidity Score Improves the Stratification of Survival in Patients With Myelodysplastic Syndrome Owing to Good Predictive Capability for Infection-related Mortality.
Sakatoku K; Takeoka Y; Miura A; Araki T; Fujitani Y; Yamamura R; Nakamae H; Ohta K; Hino M
Clin Lymphoma Myeloma Leuk; 2019 Dec; 19(12):799-805. PubMed ID: 31648956
[TBL] [Abstract][Full Text] [Related]
5. Patterns of transfusion burden in an unselected population of patients with myelodysplastic syndromes: A population-based study.
Rozema J; van Roon EN; Kibbelaar RE; Veeger NJGM; Slim CL; de Wit H; Hoogendoorn M;
Transfusion; 2021 Oct; 61(10):2877-2884. PubMed ID: 34480360
[TBL] [Abstract][Full Text] [Related]
6. Age and comorbidities deeply impact on clinical outcome of patients with myelodysplastic syndromes.
Balleari E; Salvetti C; Del Corso L; Filiberti R; Bacigalupo A; Bellodi A; Beltrami G; Bergamaschi M; Berisso G; Calzamiglia T; Carella AM; Cavalleri M; Da Col A; Favorini S; Forni GL; Goretti R; Miglino M; Mitscheuning L; Molinari E; Racchi O; Scudeletti M; Tassara R; Gobbi M; Lemoli R; Clavio M
Leuk Res; 2015 Aug; 39(8):846-52. PubMed ID: 26145790
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of comorbidities at diagnosis predicts outcome in myelodysplastic syndrome patients.
Breccia M; Federico V; Latagliata R; Mercanti C; D'Elia GM; Cannella L; Loglisci G; Salaroli A; Santopietro M; Alimena G
Leuk Res; 2011 Feb; 35(2):159-62. PubMed ID: 20594593
[TBL] [Abstract][Full Text] [Related]
8. Epidemiology and Clinical Significance of Secondary and Therapy-Related Acute Myeloid Leukemia: A National Population-Based Cohort Study.
Granfeldt Østgård LS; Medeiros BC; Sengeløv H; Nørgaard M; Andersen MK; Dufva IH; Friis LS; Kjeldsen E; Marcher CW; Preiss B; Severinsen M; Nørgaard JM
J Clin Oncol; 2015 Nov; 33(31):3641-9. PubMed ID: 26304885
[TBL] [Abstract][Full Text] [Related]
9. Comorbidity as prognostic variable in MDS: comparative evaluation of the HCT-CI and CCI in a core dataset of 419 patients of the Austrian MDS Study Group.
Sperr WR; Wimazal F; Kundi M; Baumgartner C; Nösslinger T; Makrai A; Stauder R; Krieger O; Pfeilstöcker M; Valent P
Ann Oncol; 2010 Jan; 21(1):114-9. PubMed ID: 19605505
[TBL] [Abstract][Full Text] [Related]
10. Cytogenetics and comorbidity predict outcomes in older myelodysplastic syndrome patients after allogeneic stem cell transplantation using reduced intensity conditioning.
Yucel OK; Saliba RM; Rondon G; Ahmed S; Alousi A; Bashir Q; Ciurea SO; Popat U; Khouri I; Marin D; Rezvani K; Kebriaei P; Shpall EJ; Champlin RE; Oran B
Cancer; 2017 Jul; 123(14):2661-2670. PubMed ID: 28324640
[TBL] [Abstract][Full Text] [Related]
11. Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome.
Della Porta MG; Malcovati L; Strupp C; Ambaglio I; Kuendgen A; Zipperer E; Travaglino E; Invernizzi R; Pascutto C; Lazzarino M; Germing U; Cazzola M
Haematologica; 2011 Mar; 96(3):441-9. PubMed ID: 21134982
[TBL] [Abstract][Full Text] [Related]
12. Treatment patterns in older patients with myelodysplastic syndromes: A population-based analysis reflecting the real world.
Rozema J; Graafsma J; Hoogendoorn M; Kibbelaar R; Veeger N; van Roon E;
J Geriatr Oncol; 2023 Mar; 14(2):101418. PubMed ID: 36657246
[TBL] [Abstract][Full Text] [Related]
13. Hypoalbuminemia is a surrogate biomarker of poor prognosis in myelodysplastic syndrome even when adjusting for comorbidities.
Sevindik OG; Guc Z; Kahraman S; Medeni Solmaz S; Katgi A; Acar C; Alacacioglu I; Piskin O; Ozsan GH; Demirkan F; Undar B; Ozcan MA
Leuk Lymphoma; 2015; 56(9):2552-5. PubMed ID: 25669924
[TBL] [Abstract][Full Text] [Related]
14. Improving Revised International Prognostic Scoring System Pre-Allogeneic Stem Cell Transplantation Does Not Translate Into Better Post-Transplantation Outcomes for Patients with Myelodysplastic Syndromes: A Single-Center Experience.
Alzahrani M; Power M; Abou Mourad Y; Barnett M; Broady R; Forrest D; Gerrie A; Hogge D; Nantel S; Sanford D; Song K; Sutherland H; Toze C; Nevill T; Narayanan S
Biol Blood Marrow Transplant; 2018 Jun; 24(6):1209-1215. PubMed ID: 29474870
[TBL] [Abstract][Full Text] [Related]
15. Association of comorbidities with overall survival in myelodysplastic syndrome: development of a prognostic model.
Naqvi K; Garcia-Manero G; Sardesai S; Oh J; Vigil CE; Pierce S; Lei X; Shan J; Kantarjian HM; Suarez-Almazor ME
J Clin Oncol; 2011 Jun; 29(16):2240-6. PubMed ID: 21537048
[TBL] [Abstract][Full Text] [Related]
16. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy.
Hershman D; Neugut AI; Jacobson JS; Wang J; Tsai WY; McBride R; Bennett CL; Grann VR
J Natl Cancer Inst; 2007 Feb; 99(3):196-205. PubMed ID: 17284714
[TBL] [Abstract][Full Text] [Related]
17. Comparison of demographics, disease characteristics, and outcomes between Black and White patients with myelodysplastic syndromes: A population-based study.
Lesegretain A; Brunner A; King AJ; Laadem A; Fell G; Fathi AT
Leuk Res; 2023 Feb; 125():107006. PubMed ID: 36580877
[TBL] [Abstract][Full Text] [Related]
18. Patient-related factors independently impact overall survival in patients with myelodysplastic syndromes: an MDS-CAN prospective study.
Buckstein R; Wells RA; Zhu N; Leitch HA; Nevill TJ; Yee KW; Leber B; Sabloff M; St Hilaire E; Kumar R; Geddes M; Shamy A; Storring J; Kew A; Elemary M; Levitt M; Lenis M; Mamedov A; Zhang L; Rockwood K; Alibhai SM
Br J Haematol; 2016 Jul; 174(1):88-101. PubMed ID: 26991631
[TBL] [Abstract][Full Text] [Related]
19. Incidence of secondary myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) in patients with ovarian or breast cancer in a real-world setting in the United States.
Shenolikar R; Durden E; Meyer N; Lenhart G; Moore K
Gynecol Oncol; 2018 Nov; 151(2):190-195. PubMed ID: 30268525
[TBL] [Abstract][Full Text] [Related]
20. Overall survival in lower IPSS risk MDS by receipt of iron chelation therapy, adjusting for patient-related factors and measuring from time of first red blood cell transfusion dependence: an MDS-CAN analysis.
Leitch HA; Parmar A; Wells RA; Chodirker L; Zhu N; Nevill TJ; Yee KWL; Leber B; Keating MM; Sabloff M; St Hilaire E; Kumar R; Delage R; Geddes M; Storring JM; Kew A; Shamy A; Elemary M; Lenis M; Mamedov A; Ivo J; Francis J; Zhang L; Buckstein R
Br J Haematol; 2017 Oct; 179(1):83-97. PubMed ID: 28677895
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
